🧾 What This Document Is

This is a Form 8-K filing with the SEC, which companies use to announce major news to investors. Attached to it is a press release from March 31, 2026, detailing 20/20 BioLabs' financial results for all of 2025 and recent business updates. Think of it as the company's official "year-end report card" combined with a "here's what's coming next" announcement.

🏢 What The Company Does

👉 In simple terms, 20/20 BioLabs creates AI-powered blood tests designed to catch cancer and chronic diseases early. They're a player in the hot Multi-Cancer Early Detection (MCED) market. Their main products are the OneTest™ for Cancer (to screen for multiple cancers) and the newer OneTest™ for Longevity (to assess risks for diseases like diabetes and heart disease). They run tests from their own lab in Gaithersburg, Maryland.

💰 Financial Highlights: The 2025 Scorecard

The company showed progress in growing sales and cutting losses, though it's still not profitable.

• Revenue: Grew 17% to $2.0 million in 2025, up from $1.8 million in 2024. 👉 This shows their tests are finding more customers.
• Profitability (Gross Profit): Jumped 68% to $0.6 million. The gross margin (profit left after the direct cost of making the test) expanded significantly from 20.6% to 29.6%. 👉 They're making more money on each test sold.
• Net Loss: Still losing money, but the net loss improved 33% to ($3.7 million) from ($5.6 million) the year before. 👉 The path to profitability is getting clearer.
• Cash & Spending: They burned through $1.9 million in cash for operating activities in 2025 (down from $2.6 million in 2024). They ended the year with $1.0 million in cash.
• Key Balance Sheet Items (as of Dec 31, 2025):
  • Cash: $1.0 million.
  • Total Assets: $4.1 million.
  • Total Liabilities: $4.2 million (they owe slightly more than they own).
  • Deferred Revenue: ~$0.4 million. 👉 This is cash they've received for tests not yet delivered, which is a good sign of future work.

🚀 Key Moves & Recent Milestones

This is where the company made big strategic pushes heading into 2026.

• Nasdaq Listing: Started trading on the Nasdaq under the ticker "AIDX" on February 19, 2026. 👉 This is a major credibility milestone that makes it easier for big investors to buy the stock.
• New Funding: Secured $5.0 million in February 2026 via a private investment. Even better, this deal opens the door for up to $40 million in future funding if the company hits certain goals. 👉 This solves the cash crunch and fuels growth plans.
• A Big Government Contract: Won $520,000 in state funding to provide their OneTest™ Cancer screening to 18 Maryland fire departments. This is a 225% increase from the same program last year. 👉 This proves public sector demand and could be a model for other states.
• New Product Launch: Officially launched the OneTest™ for Longevity in early 2026. They're using IBM's AI tech (watsonx.ai) to analyze risks and provide personalized advice.
• Legislative Win: The Medicare Multi-Cancer Early Detection Screening Act was signed into law in February 2026. This creates a pathway for Medicare to pay for these tests by 2028. 👉 This could massively expand their potential customer base in the future.

📦 Financial Position & What The Numbers Signal

The balance sheet tells the story of a company in transition. While they have liabilities of $4.2 million and a small negative equity, the big story is the subsequent financing. The $5 million that came in February 2026 isn't on the year-end balance sheet yet, but it fundamentally changes their financial stability. The plan for up to $40 million more gives them a war chest for expansion.

📈 What This Signals: The Big Picture

👍 Strengths:

• Proven Demand: Double-digit revenue growth and a major state contract show people want their tests.
• Getting More Efficient: Margins are up, and operating costs are down sharply (-35%).
• Strategic Funding: Access to significant capital via the Nasdaq listing and the flexible $40M funding deal.
• Favorable Regulation: New Medicare law could create a huge reimbursement market by 2028.

⚠️ Risks:

• Still Unprofitable: The company is losing money and has a history of accumulated losses.
• Cash Dependent: Until consistently profitable, it relies on investor funding to operate.
• Competitive Market: The MCED space is getting crowded with well-funded competitors.
• Execution Risk: They need to successfully commercialize the new Longevity test and scale the cancer screening business.

🔮 What's Next: The 2026 Game Plan

Management calls 2026 a potential "breakout year." Their focus is on scaling sales to markets like firefighters, veterans, and self-insured employers. They plan to aggressively market the new OneTest™ for Longevity directly to consumers. With the new law, they also intend to seek Medicare coverage for their cancer test ahead of the 2028 implementation. The deferred revenue gives them visibility into near-term sales.

🧠 The Analogy

20/20 BioLabs is like a high-growth startup that just passed a critical milestone. They've built a promising product (the test), found initial customers (like the fire departments), and just secured the venture capital (the $5M/$40M funding deal) and the IPO (Nasdaq listing) needed to scale the business. Now the real test is whether they can use that fuel to capture market share and become profitable before the cash runs out.

📇 Key Contacts & People

• Investor Relations Contact: Chris Tyson, MZ Group
  • Direct Phone: 949-491-8235
  • Email: [email protected]
• Chief Executive Officer: Jonathan Cohen (quoted extensively in the press release)

🧩 Final Takeaway

20/20 BioLabs showed solid operational progress in 2025 with growing sales and better margins. However, the real story is about the future: they've now secured the Nasdaq listing, major funding, and early government contracts that could transform them from a development-stage company into a commercial one. The next 12-18 months are critical for proving they can scale.